- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/14 - Antivirals for RNA viruses
Patent holdings for IPC class A61P 31/14
Total number of patents in this class: 12170
10-year publication summary
119
|
131
|
236
|
333
|
359
|
1433
|
1674
|
2032
|
1348
|
626
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Gilead Sciences, Inc. | 2041 |
129 |
The Regents of the University of California | 20015 |
96 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2861 |
96 |
Bristol-myers Squibb Company | 4872 |
84 |
Centre National de La Recherche Scientifique | 10476 |
76 |
Katholieke Universiteit Leuven | 1198 |
71 |
Janssen Pharmaceuticals, Inc. | 432 |
67 |
Modernatx, Inc. | 1262 |
67 |
Enanta Pharmaceuticals, Inc. | 428 |
65 |
Emory University | 1625 |
60 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3361 |
57 |
The Trustees of the University of Pennsylvania | 4328 |
51 |
BioNTech SE | 672 |
51 |
Vanderbilt University | 1910 |
50 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 832 |
48 |
Board of Regents, The University of Texas System | 5828 |
46 |
Institut Pasteur | 785 |
46 |
The Board of Trustees of the Leland Stanford Junior University | 6441 |
45 |
Pfizer Inc. | 3367 |
44 |
The Wistar Institute of Anatomy and Biology | 453 |
43 |
Other owners | 10878 |